ReviewAnnals of surgical oncology2023
The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment.
Review in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast.International medical case reports journal · 2026Article
- Characterizing the General Surgery Experience of Future Breast Surgeons: A Multi-institutional Study from the US ROPE Consortium.Annals of surgical oncology · 2025Article
- Sentinel Node Biopsy Utilization in Wisconsin Women Undergoing Breast-Conserving Surgery for DCIS.Annals of surgical oncology · 2025Article
- Lumpectomy surgery for large ductal carcinoma in situ.Breast cancer research and treatment · 2025Article
- Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ.Breast cancer research and treatment · 2025Article
- Ultrasound characteristics comparison and development of a predictive nomogram for intraductal papilloma and ductal carcinomaFrontiers in oncology · 2025Article
- Impact of surgical types on overall survival in patients with ductal carcinomaGland surgery · 2024Article
- A Look at the Other Side: High-Risk Lesions and Occult Contralateral Malignancy in Symmetry Procedures for Patients Undergoing Oncoplastic Breast-Conserving Surgery.Annals of surgical oncology · 2023Article
- Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.European journal of cancer (Oxford, England : 1990) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of ductal carcinoma in situ (DCIS) management has been driven by a parallel evolution in our understanding of its natural history. Early trials established the benefit of adjuvant therapies in all patients with DCIS. In contrast, subsequent studies have stratified patients to determine their eligibility for progressively less invasive and less intensive therapies. Large, randomized trials and meta-analyses have supported this shift away from treating DCIS as an homogenous disease treated with similar intensity to invasive breast cancer. This review describes the landmark studies on which current DCIS management is based.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.